{"nctId":"NCT03859635","briefTitle":"Erector Spinae Block Versus Surgeon Infiltration in VATS Procedures","startDateStruct":{"date":"2019-02-07","type":"ACTUAL"},"conditions":["Pain, Postoperative","Thoracic","Acute Pain"],"count":120,"armGroups":[{"label":"Ultrasound guided Liposomal Bupivacaine Erector Spinae Block","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liposomal Bupivacaine","Drug: Bupivacaine, 0.25%"]},{"label":"Ultrasound guided Standard Bupivacaine Erector Spinae Block","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bupivacaine, 0.5%"]},{"label":"Surgeon Infiltration","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liposomal Bupivacaine","Drug: Bupivacaine, 0.25%"]}],"interventions":[{"name":"Liposomal Bupivacaine","otherNames":[]},{"name":"Bupivacaine, 0.25%","otherNames":[]},{"name":"Bupivacaine, 0.5%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pt undergoing VATS including but not limited to wedge or lobectomy at Indiana University Hospital\n* ASA 1,2,3 or 4\n* Age 18 or older, male or female\n* Desires regional anesthesia for postoperative pain control\n\nExclusion criteria:\n\n* Any contraindication for Erector Spinae Plane block\n* History of substance abuse in the past 6 months which would include heroin, marijuana or any other illegal street drugs\n* Patient staying intubated after surgery\n* Patient (home dose) taking more than 30mg PO morphine equivalent per day\n* Known allergy or other contraindications to the study medications, which include dilaudid and bupivacaine.\n* Pts. scheduled for a pleurodesis, decortication or esophagectomy at Indiana University Hospital","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Endpoint of This Study Will be 24 Hours VAS Pain Score at Rest","description":"The VAS score will be taken at rest using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"2.5"},{"groupId":"OG001","value":"4.3","spread":"2.6"},{"groupId":"OG002","value":"3.3","spread":"2.3"}]}]}]},{"type":"PRIMARY","title":"The Primary Endpoint of This Study Will be 24 Hours VAS Pain Score With Movement","description":"The VAS score will be taken after movement (knee flexion) using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"2.8"},{"groupId":"OG001","value":"6.3","spread":"2.3"},{"groupId":"OG002","value":"4.5","spread":"2.9"}]}]}]},{"type":"PRIMARY","title":"The Primary Endpoint of This Study Will be 48 Hours VAS Pain Score at Rest","description":"The VAS score will be taken at rest using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"2.3"},{"groupId":"OG001","value":"3.4","spread":"2.5"},{"groupId":"OG002","value":"2.8","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Secondary Endpoint Includes Total Opioid Consumption at 72 Hours","description":"Opioid consumption between 48-72hr will be collected by a study team member per protocol time requirements","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Nausea Scores Over 72 Hours","description":"Nausea scores will be collected by a study team member post operatively up to 3 days per protocol. Nausea will be recorded as None=0, Mild=1, Moderate=2, Severe=3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.14","spread":null},{"groupId":"OG002","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Sedation Scores Over 72 Hours","description":"Sedation scores will be documented by a study team member post operatively up to 3 days per protocol requirements. Determining if patient is Awake/Alert=0, Quietly Awake=1, Asleep but Arousable=2, or Deep Sleep=3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.03","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Overall Satisfaction Scores at Hour 24","description":"Subjects will be followed up at 24 hours post operatively by a study team member to document patient overall satisfaction scores. The scores are collected as Very Unsatisfied=0, Unsatisfied=1, Neutral=2, Satisfied=3, Very Satisfied=4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Overall Satisfaction Scores at Hour 48","description":"Subjects will be followed up at 48 hours post operatively by a study team member to document patient overall satisfaction scores. The scores are collected as Very Unsatisfied=0, Unsatisfied=1, Neutral=2, Satisfied=3, Very Satisfied=4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Endpoint Includes Total Opioid Consumption at 48 Hours","description":"Opioid consumption at 24-48hr post op will be collected by a study team member per protocol time requirements","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Endpoint Includes Total Opioid Consumption at 24 Hours","description":"Opioid consumption at 1-24 hr postop will be collected by a study team member per protocol time requirements","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Endpoint Includes Total Opioid Consumption at 1 Hour","description":"Opioid consumption at 1hr will be collected by a study team member per protocol time requirements","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"The Primary Endpoint of This Study Will be 48 Hours VAS Pain Score With Movement","description":"The VAS score will be taken after movement (knee flexion) using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"2.6"},{"groupId":"OG001","value":"5.3","spread":"2.4"},{"groupId":"OG002","value":"3.8","spread":"2.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["Ileus","Respiratory Depression"]}}}